• Durect Corp., of Cupertino, Calif., said top-line data from its Phase III BESST (Bupivacaine Effectiveness and Safety in SABER) study of Posidur in postoperative pain relief failed to reach statistical significance, though results trended positive for both pain reduction and reduction of supplemental opioid use in the first three days after surgery. The study enrolled a total of 305 patients undergoing a variety of general abdominal surgical procedures. Shares of Durect (NASDAQ:DRRX) plunged 34 percent, or 44 cents, to close Friday at 74 cents.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter